Survival in the United Kingdom Medical Research Council AML trials 1970–1999 for patients aged 15–59 years.
E1308: A Phase II Trial of Induction Chemotherapy Followed by Cetuximab with Low Dose vs. Standard Dose IMRT in Patients with HPV-Associated Resectable.
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Approach to Young, High Risk AML patients with Limited Resources
